Gonococcal antimicrobial susceptibility surveillance in Europe – 2010
In 2010, 21 EU/EEA Member States participated in the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), testing a total of 1766 isolates.
Euro-GASP 2010 identified a significant increase in the proportion of tested isolates that show decreased susceptibility to cefixime, from 4% in 2009 to 9% in 2010, using a cut-off of &gt;0.125 mg/L. Rates of ciprofloxacin and azithromycin resistance remain high (53% and 7%, respectively).
The rapid increase and spread of decreased susceptibility to cefixime is extremely concerning as cefixime is a recommended therapy for gonorrhoea across Europe, as is ceftriaxone.
Antimicrobial consumption - Annual Epidemiological Report for 2019
18 Nov 2020 - In 2019, the average total (community and hospital sector combined) consumption of antibacterials for systemic use (Anatomical Therapeutic Chemical (ATC) group J01) in the EU/EEA was 19.4 defined daily doses (DDD) per 1 000 inhabitants per day (country range: 9.5–34.1). During the period 2010–2019, a statistically significant decrease was observed for the EU/EEA overall.
Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report for 2019
18 Nov 2020 - This report is based on data reported to the European Antimicrobial Resistance Surveillance Network (EARS-Net) for the period 2015 to 2019, retrieved from The European Surveillance System (TESSy) and ECDC’s decentralised data storage for antimicrobial resistance and healthcare-associated infections (ARHAI) on 10 September 2020.
Influenza virus characterisation, October 2020
13 Nov 2020 - This is the first report for the 2020–2021 influenza season. As of week 44/2020, only 39 influenza detections across the WHO European Region had been reported to The European Surveillance System (TESSy); 59% type A viruses, with A(H3N2) prevailing over A(H1N1)pdm09, and 41% type B viruses with none having been ascribed to a lineage. This represents a 97% drop in detections compared with the same period in 2019, probably due to the COVID-19 pandemic and measures introduced to combat it.